(Partial video transcript; please use link to view video or complete transcript)

Researchers at Baylor College of Medicine and Texas Children's Hospital have uncovered a potential Achilles heel of

Study achieved median overall survival of 31.7 months
Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response
INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form

The FDA has approved ruxolitinib (Jakafi) for the treatment of patients 12 years and older with chronic

If you’re receiving treatment for

Abstract

According to the results of a study presented at the Annual Meeting of the Society of Hematologic Oncology (SOHO), graft vs host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (PTCy) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) does not appear to be associated with an increased risk in bacterial, viral, or fungal infections.

While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study found.

On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

Efficacy was evaluated in KD025-213 (NCT03640481), a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic GVHD who were treated with belumosudil 200 mg taken orally once daily.